- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
- Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
- Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
- Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
More ▼
Key statistics
As of last trade Corcept Therapeutics Inc (CORT:NAQ) traded at 30.10, -14.55% below its 52-week high of 35.22, set on Jun 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 30.34 |
---|---|
High | 31.00 |
Low | 30.00 |
Bid | 30.08 |
Offer | 30.11 |
Previous close | 30.50 |
Average volume | 930.87k |
---|---|
Shares outstanding | 104.11m |
Free float | 92.26m |
P/E (TTM) | 28.53 |
Market cap | 3.18bn USD |
EPS (TTM) | 1.07 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:23 BST.
More ▼